<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102471">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842360</url>
  </required_header>
  <id_info>
    <org_study_id>MV130-SLG-001</org_study_id>
    <secondary_id>2012-003253-28</secondary_id>
    <nct_id>NCT01842360</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>MV130</acronym>
  <official_title>Randomized Double-blind Placebo-controlled Prospective, Parallel, Multicentre Clinical Trial of Bacterial Vaccine Administered by Sublingual Mucosa in Subjects With COPD for Efficacy and Safety Evaluation and Immunomodulatory Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of a biological vaccine
      (MV130 in subjects with Chronic Obstructive Pulmonary Disease (COPD) compared with a placebo
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind parallel placebo controlled study. The subjects will receive medication during
      12 months and will be followed up during another six months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Decrease in the number of COP exacerbations.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First COPD exacerbation</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of drugs</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The drugs consumption will be evaluated  as follows:
Antibiotic: 1 point
Inhaled corticosteroids: 2 points
Systemic corticosteroids: 3 points
O2: 4 points
Ventilation: 5 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visit to the doctor due to COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits to the emergency service</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations due to COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization due to COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in COPD Assessment Test (CAT)</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health costs during COPD exacerbations</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in immunological parameters</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specific Humoral Response (Serum immunoglobulin G against the vaccine bacterial antigens; salivary immunoglobulin A concentrations versus vaccine antigens) by ELISA.
Specific proliferative response of T cells (cluster of differentiation3 + / cluster of differentiation 4 + and cluster of differentiation 3 + / cluster of differentiation 8 +) in vitro following stimulation with bacterial antigens comprising the vaccine) by (carboxyfluorescein diacetate succinimidyl ester) CFSE labeling and flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with local reactions</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>MV130</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will receive daily dose of MV130 during 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive daily dose of placebo during 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The subjects will receive daily dose of placebo during 12 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MV130</intervention_name>
    <description>The subjects will receive daily dose of MV130 during 12 months</description>
    <arm_group_label>MV130</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Both gender

          -  Age between 35 and 85.

          -  Must be able to follow the treatment regimen

          -  Diagnosis of moderate COPD according to GOLD criteria

          -  Consumption of 10 or more packs of cigarettes/year

          -  Fertile women of must use an approved contraceptive method

        Exclusion Criteria:

          -  Pregnant women, breastfeeding

          -  Subject who has participated in a study or clinical trial with an investigational
             product in the last 3 months before inclusion

          -  Subject with severe COPD

          -  Subject with a history of hypersensitivity to any component of the vaccine

          -  Subject outside of age range

          -  Subject diagnosed with asthma

          -  Subject who has had an exacerbation 4 weeks before starting the trial.

          -  Subject that have needed corticosteroids in the last 4 weeks before starting the
             trial

               -  Subject diagnosed with Primary or Secondary Immunodeficiency Subjects with
                  chronic lymphoproliferative disease

               -  Subjects with chronic infectious disease

               -  Subject with chronic heart disease, arrhythmias, or episodes of arrhythmia
                  secondary to the administration of bronchodilators.

               -  Subject diagnosed with COPD and chronic colonization by Pseudomonas aeruginosa
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Fernández-Cruz, MD-PhD-prof</last_name>
    <role>Study Director</role>
  </overall_official>
  <overall_official>
    <last_name>Javier Miguel Díez, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>José Luis Alvarez-Salas, MD-PhD-prof,</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>María Jesús Buendía, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Fernández-Cruz, MD, PhD</last_name>
    <phone>34915868423</phone>
    <email>efernanedzc.hgugm@salud.madrid.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <phone>34916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de Miguel, MD</last_name>
      <phone>34915868000</phone>
      <email>jmiguel.hgugm@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier de Miguel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Álvarez-Sala, MD-PhD- prof</last_name>
      <phone>34913303045</phone>
      <email>jlaw@separ.es</email>
    </contact>
    <investigator>
      <last_name>José Luis Alvarez-Sala, MD-PhD-prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Jesús Buendía García, MD</last_name>
      <phone>34911918000</phone>
      <email>mbuendia.huil@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Buendía María Jesús, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
